基本信息
views: 100
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Tengfei Ted Xiao is a Co-Founder and the Chief Technology Officer of GV20 Oncotherapy. Ted founded GV20 Oncotherapy in 2016, after he finished his postdoctoral research training in Myles Brown lab at Dana-Farber Cancer Institute (DFCI). He was a pioneer of building up a functional CRISPR screening platform at DFCI. His expertise includes cancergenomics, high throughput screening techniques and bioinformatics. In GV20, he leads teams to build an AI-based antibody screening platform and has discovered several novel targets for cancer immunotherapy.
Research Interests
Papers共 50 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
X. Shirley Liu, Yulong Li, Xiangyang Wu,Hailing Liu,Huizhu Liu,Caibin Sheng,Qingyang Ding, Yixuan Tang, Chao Liu, Bin Xie, Xi Xiao, Quan Yu,
Cancer Researchno. 6_Supplement (2024): 3914-3914
Bin Xie, Yulong Li,Karim A Benhadji,X Shirley Liu, Xiangyang Wu, Hailing Liu, Xi Xiao,Huizhu Liu,Qingyang Ding,Caibin Sheng,Rongbin Zheng, Quan Yu,
Journal for ImmunoTherapy of Cancerno. Suppl 1 (2023)
Cancer Researchno. 4 (2022): P4-01
Proceedings of the National Academy of Sciencesno. 3 (2022): e2105898119-e2105898119
Xiaoshuang Wang,Mei Feng,Tengfei Xiao, Baosen Guo,Danyang Liu,Chenglong Liu,Jinpeng Pei,Qiaofeng Liu, Yi Xiao,Rina Rosin-Arbesfeld,Ying Shi,Yang Zhou,
biorxiv(2020)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn